- For patients with type 2 diabetes (T2D) and dyslipidemia, statins may slow progression of vision-threatening retinopathy and reduce subsequent retinal laser treatments, intravitreal injections, and vitrectomies.
Why this matters
- Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults.
- Claims data analysis of 18,947 Taiwanese patients with T2D and dyslipidemia on statins (and no other lipid-lowering drugs), propensity-matched with 18,947 not taking statins.
- Funding: Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- DR was present in 10.6% and 12.0% of the statin and nonstatin groups, respectively.
- Compared with the nonstatin group, those taking statins had significantly lower rates of (HRs; 95% CIs):
- DR: 0.86 (0.81-0.91);
- Nonproliferative DR: 0.92 (0.86-0.99);
- Proliferative DR: 0.64 (0.58-0.70);
- Vitreous hemorrhage: 0.62 (0.54-0.71);
- Tractional retinal detachment: 0.61 (0.47-0.79);
- Macular edema: 0.60 (0.46-0.79);
- Retinal laser treatments: 0.71 (0.65-0.77);
- Intravitreal injections: 0.74 (0.61-0.89);
- Vitrectomy: 0.58 (0.48-0.69);
- Major adverse cardiovascular events: 0.81 (0.77-0.85);
- New-onset diabetic neuropathy: 0.85 (0.82-0.89);
- New-onset diabetic foot ulcers: 0.73 (0.68-0.78).
- Lipid profiles and biomarkers for BP and serum glucose unavailable.
- No data on eye laterality.
- All-Asian population.
- Retrospective design.